BiocurePharm Looks Beyond North America Via Canada IPO
With a business model that sets it apart from other South Korean bioventures, BiocurePharm plans to set up manufacturing facilities in North America and worldwide with local partners, and is launching a Canadian IPO in a bid to transform into a truly multinational operation, its CEO says.
You may also be interested in...
Stockholm-based Xbrane Biopharma plans to be the first to sell a biosimilar version of Lucentis in Iran as part of its strategy to leverage patent gaps in emerging markets for high-priced drugs.
VC Investment in South Korea’s biopharma sector drops again as investors continue to shy away amid higher interest rates and reduced out-licensing deals.
Scrip takes a look at the current landscape in the South Korean digital therapeutics sector, where some remaining gaps in regulation and reimbursement are seen but multiple products are now progressing through pivotal local clinical trials.